Systemic Sclerosis - PowerPoint PPT Presentation

1 / 66
About This Presentation
Title:

Systemic Sclerosis

Description:

Systemic Sclerosis Dan Mandel, MD UCI School of Medicine – PowerPoint PPT presentation

Number of Views:485
Avg rating:3.0/5.0
Slides: 67
Provided by: DTC57
Category:

less

Transcript and Presenter's Notes

Title: Systemic Sclerosis


1
Systemic Sclerosis
  • Dan Mandel, MD
  • UCI School of Medicine

2
Systemic Sclerosis (definition)
  • Multisystem disorder
  • Unknown etiology
  • Thickening of skin caused by accumulation of
    connective tissue (collagen types I and III)
  • Involvement of visceral organs

3
Epidemiology
  • Peak age range 35-64
  • Younger age in women and with diffuse disease.
  • FemaleMale 31
  • 81 in child bearing years
  • Incidence 20/million per year in US
  • Prevalence 240/million in US.

4
Etiology
  • Unknown
  • Environmental Exposures
  • Silica exposure in men conferred increased risk
  • Silicone breast implants no definite risk
    identified
  • Aniline laced Contaminated rapseed oil in Spain
  • Vinyl chloride exposure increased risk of SSc
    like disorder Eosinophilic Fasciitis
  • bleomycin
  • L-tryptophan Eosinophilia Myalgia syndrome

5
Etiology
  • Genetic Factors
  • Familial Clustering 1.5-2.5 of those with 1st
    degree relative
  • Choctow Native Americans prevalence
    4720/million.
  • HLA-haplotypes there are higher risk haplotypes
    in certain populations

6
Pathogenesis general principles
  • Endogenous or exogenous pathogen stimulates
    antigen presenting cells.
  • Antigen presenting cells stimulate CD4 T cells
  • Cytokines are produced by both of these cells.
  • Cytokines stimulate growth factors to stimulate
    fibroblasts to produce collagen
  • Vascular damage occurs with thickened intima and
    narrowing of the lumen.
  • Narrowing of the lumen leads to ischemia.
  • Ischemia leads to prostacyclin production which
    is a platelet aggregant and platelets bind to
    endothelium and release PDGF which is chemotactic
    and mitogenic for fibroblasts.

7
Pathogenesis
8
Pathogenesis of Scleroderma
Up to Date
9
Forms of Systemic Sclerosis
  • Limited Scleroderma
  • Skin thickening is distal to elbows and knees,
    not involving trunk
  • Can involve perioral skin thickening (pursing of
    lips)
  • Less organ involvement
  • Seen in CREST syndrome
  • Isolated pulmonary hypertension can occur
  • Diffuse Scleroderma
  • Skin thickening proximal to elbows and knees,
    involving the trunk
  • More likely to have organ involvement
  • Pulmonary fibrosis and Renal Crisis are more
    common.

10
2013 ACR Diagnostic Criteria
11
Limited Scleroderma
  • More gradual process
  • Can have Raynauds for years (even up to decade)
  • Skin involvement distal to elbows and knees
  • Often with perioral involvement (pursing of lips)
  • Capillaroscopy
  • with dilated capillary loops but without dropout.
  • Less organ involvement
  • though 10-15 with isolated pulmonary
    hypertension.
  • Renal involvement is rare.
  • Anti-centromere Ab in 70-80

12
Limited Scleroderma
  • CREST Syndrome
  • Calcinosis
  • Raynauds
  • Esophageal Dysmotility
  • Sclerodactyly
  • Telangiectasisa

A.D.A.M. Images
13
CREST Syndrome
ACR and Mayo Foundation
14
Calcinosis on x-ray
Gupta E., et al. Malaysian Family Physician.
20083(3)xx-xx
ACR
15
Nailfold Capillaroscopy
16
Diffuse Scleroderma
  • More Rapid Process
  • Often with onset of skin thickening within a year
    of Raynauds symptoms
  • Skin involvement proximal to elbows and knees
  • Often can involve the trunk
  • Capillaroscopy reveals dropout
  • With capillary dilatation and dropout.
  • Early organ involvement
  • Renal, interstitial lung disease, myocardial,
    diffuse gastrointestinal often within the first
    3 years.
  • Antibodies
  • Anti-Scl-70, anti-RNA Polymerase III.

17
Diffuse Scleroderma
ACR
Netter
American Osteopathic College of Dermatology,
Grand Rounds
18
Organs Involved
  • Skin
  • Musculoskeletal
  • Pulmonary
  • Renal
  • Gastrointestinal
  • Cardiac

19
Skin Involvement
  • Early stages
  • Perivascular infiltrate which are primarily T
    cells.
  • Skin swelling which eventually becomes skin
    thickening.
  • Involves the hands and/or feet (distal).
  • Late Stages
  • Finger-like projections of collagen extend from
    the dermis to the subcutaneous tissue to anchor
    skin deeper.
  • Skin becomes firm, thick and tight.
  • Skin thickening moves proximally.
  • Fibroblasts and collagen deposition.
  • Hair and wrinkles overlying area of skin
    thickening disappears.

20
Skin involvement in Scleroderma
  • May regress on its own over years
  • reverse pattern (ie, starting with regression of
    skin thickening in the trunk, then proximal
    extremities, then more distal).
  • Digital Ulcers
  • on extensor surface of PIPs and elbows may
    become secondarily infected.
  • Digital ischemia
  • with pits in the distal aspect of the digits
    related to prolonged Raynauds.
  • Thinning of the lips, beak-like nose.

21
Skin Manifestations
ACR
Sclero.org International Scleroderma Network
Kahaleh B. Rheum Dis Clin N Amer 200857-71
22
Musculoskeletal
  • Arthritis
  • in gt 50 with swelling, stiffness, and pain in
    the joints of the hands.
  • Carpal Tunnel Syndrome.
  • Contractures
  • related to skin thickening.
  • Polymyositis
  • may occur as part of mixed connective tissue
    disease or overlap.

23
Pulmonary
  • leading cause of death
  • since we are better at control of renal disease.
  • Symptoms
  • exertional dyspnea
  • Types of lung Involvement
  • Interstitial lung disease.
  • Isolated pulmonary hypertension.

24
Interstitial Lung Disease
  • Inflammatory phase
  • with ground glass opacities and linear
    infiltrates
  • lower 2/3 of the lung fields on CT scan.
  • Fibrosis
  • Late phase with honeycombing.
  • Diagnosis
  • Pulmonary function tests
  • restrictive pattern with low FVC, low residual
    volume, low DLCO.
  • High Resolution CT Scan
  • BAL often not required
  • Lung biopsy often not required
  • ILD is most commonly associated with diffuse
    scleroderma.
  • Anti-Scl-70

25
Interstitial Lung Disease
Up to Date 2005
Up to Date 2005
26
Primary Pulmonary Hypertension
  • Symptoms
  • exertional dyspnea.
  • Frequency
  • 10-15 of patients with systemic sclerosis
  • Definition
  • Mean PA blood pressure gt25mmHg at rest or gt30mmHg
    with exercise on right heart catheterization.
  • Estimated systolic pulmonary artery pressure of
    gt35mmHg on Echocardiogram
  • Pathogenesis
  • Intimal fibrosis and medial hypertrophy of the
    pulmonary arterioles and arteries.

27
Pulmonary Hypertension
Doppler Echocardiogram to estimate pulmonary
artery pressure. Roberts JD. Pulm Circ
20111160-181.
Up to Date 2005
28
Other Pulmonary Associations
  • Pneumonia
  • due to aspiration secondary to GERD skin
    thickening of chest may reduce effectiveness of
    cough.
  • Alveolar carcinoma increased incidence
  • Bronchogenic carcinoma increased incidence.

29
Renal Manifestations of Systemic Sclerosis
  • Scleroderma Renal Crisis
  • Abruptly developing severe hypertension
  • Rise in SBP by gt 30 mmHg, DBP by gt 20 mm Hg
  • One of the following
  • Increase in serum creatinine by 50 over baseline
    or creatinine gt 120 of upper limit.
  • Proteinuria gt 2 by dipstick.
  • Hematuria gt 2 by dipstick or gt 10 RBC/HPF
  • Thrombocytopenia lt 100
  • Hemolysis (schisctocytes, low platelets,
    increased reticulocyte count).
  • Can cause headache, encephalopathy, seizures, LV
    failure.
  • 90 with blood pressure gt 150/90.
  • Can occur also with lower blood pressures lt
    140/90 and this confers worse prognosis.

Steen et al., ClinExp. Rheumatol. 2003
30
Scleroderma Renal Crisis
Up to Date 2012
31
Risk Factors for Renal Crisis
  • Rapidly progressive skin thickening within the
    first 2-3 years.
  • Steroid use (prednisone gt 15 mg)
  • Anti-polymerase III Ab.
  • Pericardial Effusion.

32
Treatment of Scleroderma Renal Crisis
  • Medical Emergency generally with admission.
  • Initiation of ACE inhibitors such as captopril
    lifelong treatment with ACE inhibitors.
  • Dose escalation of captopril.
  • ACE-inhibitors do not prevent SRC.

33
Treatment of Scleroderma Renal Crisis
Without
Steen, Clinics in Dermatology, 1994
34
Renal Crisis - Prognosis
  • Improved overall with ACE-inhibitors.
  • Even with ACE-inhibitors 20-50 will progress to
    ESRD.
  • Among patients who required dialysis during the
    acute phase, an appreciable proportion (40-50)
    will be able to discontinue dialysis.

35
Gastrointestinal Manifestations
  • Esophageal dysmotility in up to 90.
  • Pathophysiology
  • reduced tone of gastroesophageal sphincter and
    distal dilatation of the esophagus.
  • Lamina propia and submucosal tissue with
    Inflammatory changes and increased collagen on
    pathology.
  • Symptoms
  • Dysphagia, GERD many asymptomatic.
  • Diagnosis
  • Esophageal manometry, Esophagram, CT scan.
  • Treatment
  • Proton Pump Inhibitors
  • Elevation of head of the bed.
  • Complications
  • Barrets Esophagus.

36
Gastrointestinal Manifestations
  • Gastric Involvement
  • Symptoms Early satiety.
  • Diagnosis Nuclear Gastric Emptying Test.
  • Treatment promotility agents
  • Watermelon Stomach dilated vessel which can
    cause bleeding.
  • Small Intestinal involvement
  • Symptoms distension, pain, bloating,
    steatorrhea
  • nutritional deficiencies secondary to bacterial
    overgrowth.
  • Vitamin B6/B12/folate/25-OH Vit D, low albumin
  • Diagnosis
  • glucose hydrogen breath test
  • Low D-xylose absorption test
  • small bowel aspiration (only if resistance to
    rotating antibiotics)
  • Treatment Rotating antibiotics, Reglan,
    Erythromycin

Image of Watermelon Stomach University of
Michigan Rheumatology Website
37
Gastrointestinal Manifestations
  • Colon Involvement
  • Can cause symptoms of constipation due to
    decreased peristalsis.
  • Fecal incontinence can occur due to alterations
    of internal and external sphincter.

38
Cardiac Manifestations
  • Forms of cardiac involvement
  • Pericardial Effusion
  • symptomatic pericarditis in 20
  • Microvascular CAD
  • recurrent vasospasm of coronary arteries
  • Necrosis
  • patchy myocardial fibrosis leads to diastolic gt
    systolic dysfunction.
  • Myocarditis
  • Inflammation which leads to fibrosis
  • Arrhythmias and conduction abnormalities
  • Fibrosis of cardiac conduction system.
  • AV conduction defects and arrhythmias.

39
Cardiac Involvement
Cardiac Manifestation Prevalence Diagnosis Treatment
Myocarditis Rare Cardiac MRI, Biopsy Cytoxan steroids
Pericardial effusion 5-16 Echocardiogram None NSAIDs if symptomatic
Microvascular CAD gt 60 MRI/nuclear medicine Calcium channel blockers
Macrovascular CAD 25 Coronary Angiogram Stenting/medical tx
Bradyarrhythmias Rare EKG/Holter Pacemaker
Tachyarrhythmias 15 EKG/Holter Diltiazem, ablation, defibrillator
Adapted from Desai, et al Curr Opin Rheumatol
2011m 23545-554
40
Scleroderma Autoantibodies
Antigen ANA Pattern Frequency Clinical Associations Organs Involved
Scl-70 (topoisomerase 1) Speckled 10-40 dcSSC Lung fibrosis
RNA Polymerase III Speck/Nuc 4-25 dcSSC Renal, Pulmonary HTN
Centromere Centromere 15-40 lcSSc, CREST Pulmonary HTN Esophageal
U1-RNP Speckled 5-35 lcSSC, MCTD Muscle
U3 RNP (fibrillarin) Nucleolar 1-5 dcSSC, poor prognosis Muscle Pulmonary HTN
PM-SCL Nucleolar 3-6 Overlap, mixed Muscle
Th/To Nucleolar 1-7 lcSSc Pulmonary HTN, Lung fibrosis, Small bowel
Anti U11/U12 Nucleolar 1-5 lcSSc dcSSC Lung Fibrosis
Anti-Ku 1-3 Overlap Ssc Muscle, Joint, SLE overlap
Adapted from Nihtyanova SI, Denton CP. Nat Rev
Rheumatol 2010 6112
41
Scleroderma Treatment
  • Depends on clinical manifestations
  • Aggressive disease versus stable disease
  • Reversible inflammation vs Vasoconstriction.
  • Organ Involvement
  • Treatment is directed at organ involved.

42
Raynauds
  • Calcium Channel Blockers nifedipine
  • Nitroglycerin patches
  • Sildenafil (Viagra) (but not in combination with
    nitroglycerine) usually for refractory
    Raynauds.
  • Parental vasodilators (iloprost) for severe
    disease with impending digital ischemia.

43
Gastrointestinal Involvement
  • GERD
  • Proton pump inhibitor.
  • Delayed Gastric Emptying and peristalis disorders
  • Supportive
  • Promotilants are sometimes used.

44
Pulmonary Involvement
  • Interstitial Lung Disease with active
    inflammation
  • Mycophenolate
  • Azithioprine
  • Cytoxan - IV
  • plus lower dose of steroids if RNA Poly III neg
    (ie 10 mg daily) avoid steroids if RNA Poly III
    positive.
  • Pulmonary Hypertension
  • Vasodilators bosentan, sildenafil, epoprostenol,
    treprostinil, iloprost.
  • Lung Heart Transplant

45
Myositis
  • Polymyositis overlap or MCTD
  • Similarly to myositis alone with methotrexate,
    azathioprine in combination of low dose steroids.
  • Tend to keep prednisone dose at around 10 mg or
    less to avoid risk of renal crisis.

46
Cardiac Involvement
  • Pericarditis
  • NSAIDs
  • Drainage of effusion if tamponade
  • Myocarditis with elevated CK-MB troponin
  • If CAD is excluded, MRI and biopsy confirms, then
    treatment would generally be with low dose
    prednisone (10 mg/day) and cytoxan nifedipine
    may also be helpful.

47
Skin Disease
  • Stable disease no treatment
  • Advancing diffuse skin involvement
  • Methotrexate
  • Mycophenolate
  • Current trial with Tocilizumab (Actemra)
  • D-penicillamine 125 mg/day.
  • Research on various anti-fibrosis therapies is
    being performed (imatinib, Gleevac).

48
Differential Diagnosis
  • Scleredema
  • No Raynauds, negative antibodies, seen in IDDM
  • Proximal skin thickening (trunk, shoulders, back)
  • Scleromyxedema
  • Skin thickening/induration on head, neck, arms,
    trunk
  • Monoclonal gammopathy (multiple myeloma/AL
    amyloid)
  • Skin biopsy differentiates.
  • Endocrinologic diabetes and hypothyroid myxedema
  • Can be associated with skin induration.
  • In diabetes can have sclerodactyly (Diabetic
    Cheiroarthropathy) - dorsal
  • POEMS (polyneuropathy, organomegaly,
    endocrinopathy, monoclonal gammopathy, skin
    thickening).
  • Nephrogenic Systemic fibrosis
  • Chronic kidney disease and gadolinium MRI
    contrast
  • Can involve hands and feet.
  • Eosinophilic fasciitis
  • Hands and feet are spared, peripheral blood
    eosinophilia, peau de orange appearance
  • Diagnosis is via skin biopsy.
  • Graft versus Host disease
  • History of bone marrow transplant, no Raynauds
    symptoms.

49
Cases
50
Case 1
  • 50 year old female who has CREST syndrome with
    anti-centromere antibody
  • Raynauds controlled with nifedipine
  • only digital skin thickening of the hands which
    is unchanged
  • GERD on omeprazole
  • telangiectasia.
  • She currently has no complaints.
  • Labs
  • CMP, CBC, ESR, CRP, total CK all normal,
    anti-centromere Ab positivity.
  • Echocardiogram and PFTs 1 month ago
  • Echo normal with normal estimated PA pressures.
  • PFTs normal lung volumes, normal DLCO.
  • What is next step

51
Case 1
  • Renew medications
  • Nifedipine and omeprazole
  • This case highlights the most typical case seen
    in clinics with stable disease.
  • Things to watch for
  • Change in skin disease
  • Periodic echocardiogram and PFTs.
  • General exam

52
Case 2
  • 60 year old male with Raynauds for 4 months
    prior to onset of skin involvement
  • Skin thickening has ascended to involve proximal
    extremities, chest, and abdomen within 1 year.
  • The patient reports mild shortness of breath
    recently.
  • Exam
  • Vitals T 98.9, BP 124/73, pulse 80, resp rate 18
  • Raynauds is noted without digital ulcer.
  • Cardiovascular exam normal.
  • Gastrointestinal exam is normal.
  • Dry crackles noted at both bases.
  • Extremities no edema.
  • Labs
  • CBC, CMP, total CK are all normal
  • ESR 35, CRP 1.8 (upper limit of normal is 1.0).
  • Anti-Scl-70 Ab positive, RNA Pol III negative.
  • What is next step?

53
Case 2
Strek, ME. Amer Col Chest Physicians 2012
Learningradiology.com
Oikonomou A, Prassopoulos P - Insights Imaging
(2012)
  • PFTs TLC decreased 80 to 55, VC decreased 85
    to 50, RV decreased 83 to 62, DLCO decreased
    75 to 45.
  • Bronchoscopy performed all cultures cytology
    negative (neutrophils and eosinophils are
    present).
  • Echocardiogram no pulmonary hypertension.
  • Lung Biopsy shown on right.
  • What is the diagnosis? What is the treatment?

54
Case 2
  • Interstitial lung disease associated with
    scleroderma with active inflammation.
  • Mycophenolate, Cytoxan, or Azathioprine
  • Prednisone (low dose) 10 mg daily gradual taper

55
Case 3
  • 50 year old female presents with
  • onset of Raynauds for 1 year,
  • developed skin thickening from the digits of the
    hands to just distal to the elbows.
  • She has noticed difficulty getting out of chairs
    and lifting objects overhead.
  • Exam
  • VS Temp 98.2, BP 124/72, pulse 78, respiratory
    rate 16
  • Cardiovascular and pulmonary exams normal.
  • Gastrointestinal exam is normal.
  • Muscle weakness of thighs and shoulder regions is
    noted.
  • No skin lesions other than skin thickening.
  • Labs
  • CBC, chem-7, ESR, CRP all normal, PM-SCL Ab
    positivity
  • Total CK 3000 (mostly CKMM), AST 158, ALT 105,
    GGT normal.
  • What is the next step?

56
Case 3
EMG, Nerve Conduction Studies
Seidman, RJ. Medscape
Olsen NJ, et al. Rheum Dis Clin N. Amer
199622(4)783-796
  • MRI of the thigh
  • Biopsy of thigh musculature
  • What is the diagnosis? What is the treatment?

57
Case 3
  • Scleroderma/Myositis overlap.
  • Methotrexate or Azathioprine
  • Low dose prednisone 10 mg daily
  • Over the next few months, CK levels normalize and
    prednisone dose is gradually tapered, and the
    patients strength improves.

58
Case 4
  • 35 year old female with
  • limited scleroderma for 3 years, anti-centromere
    Ab positive.
  • with stable skin disease involving the digits of
    the hands only new rash appeared 1 month ago,
    gradually worsening, no change in last week.
  • Raynauds have been quite severe, but not on
    therapy.
  • Exam
  • VS Temp 97.9, BP 123/76, pulse 82, RR 16
  • Cardiac, pulmonary, gastrointestinal exams
    normal, no edema
  • Skin see next slide

59
Case 4
Sclero.org International Scleroderma Network
  • Labs
  • CBC, CMP, ESR, CRP all normal anti-centromere Ab
    positive, anti-phospholipid Ab neg, echo with
    bubble study negative
  • What is the diagnosis? What is next step?

60
Case 4
  • Digital Ischemia due to Raynauds
  • Start calcium channel blocker
  • Nifedipine 30 mg PO daily.
  • Close follow-up and increase dose of nifedipine
    as blood pressure tolerates.
  • If not responding
  • Can start nitroglycerin patch or can start
    sildenafil (not both).

61
Case 5
  • 58 year old male with
  • Rapid onset scleroderma with Raynauds for 6
    months then skin thickening that spread to
    proximal arm, proximal thigh, chest, and abdomen
    within 1.5 years.
  • Blood pressure generally runs 110/70
  • has mild headache, and has noticed some swelling
    of the legs.
  • Exam
  • VS Temp 98.4, BP 160/105, pulse 70, RR 16.
  • Cardiac, pulmonary, gastrointestinal exam all
    normal neurologic exam is non-focal.
  • There is only mild bilateral lower extremity
    edema.

62
Case 5
  • Labs
  • Creatinine 2.0 (baseline is 0.6), CBC normal, ESR
    and CRP normal, urine with 1 protein, no RBC or
    WBC known to be RNA Pol III positive.
  • What is the diagnosis? What is the next step.

63
Case 5
  • Scleroderma Renal Crisis
  • Treatment
  • Hospitalization
  • Start ACE-inhibitor captopril with dose
    escalation.

64
References
  • Medscape
  • Up To Date
  • Desai, et al Curr Opin Rheumatol 2011
    23545-554
  • Curr Opin Rheumatol 23505-510
  • Fischer A CHEST 2006 130976 981
  • Rheum Dis Clin N Am200329293313
  • Arthritis Rheum 2006543962-3970
  • Rheumatology 200948iii32iii35
  • Steen VD Rheum Dis Clin N Am 200329315333
  • Hudson M, et al Medicine 201089976-981
  • Bon LV Curr Opin Rheumatol 201123505510
  • Barnes J Curr Opin Rheumatol 2012, 24165170

65
Definition of Criteria
66
Skin Scoring
Write a Comment
User Comments (0)
About PowerShow.com